<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30195330</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>14</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1608-3040</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>83</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jun</Month>                    </PubDate>                </JournalIssue>                <Title>Biochemistry. Biokhimiia</Title>                <ISOAbbreviation>Biochemistry Mosc.</ISOAbbreviation>            </Journal>            <ArticleTitle>Implication of Integrin α2β1 in Proliferation and Invasion of Human Breast Carcinoma and Melanoma Cells: Noncanonical Function of Akt Protein Kinase.</ArticleTitle>            <Pagination>                <MedlinePgn>738-745</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1134/S0006297918060111</ELocationID>            <Abstract>                <AbstractText>Blocking the expression of integrin α2β1, which was accomplished by transduction of α2-specific shRNA, resulted in significant inhibition of proliferation and clonal activity in human MCF-7 breast carcinoma and SK-Mel-147 melanoma cells. Along with these changes, deprivation of α2β1 caused a sharp decrease in melanoma cell invasion in vitro. Analysis of integrin-mediating signal pathways that control cell behavior revealed a significant increase in activity of Akt protein kinase in response to depletion of α2β1. The increase in Akt activity that accompanies a suppressive effect on cell invasion contradicts well-known Akt function aimed at stimulation of tumor progression. This contradiction could be explained by the &quot;reversed&quot; (noncanonical) role played by Akt in some cells that consists in suppression rather than promotion of invasive phenotype. To test this suggestion, the effects of Akt inhibitors on invasive activity of SK-Mel-147 cells were investigated. If the above suggestion is true, then inhibition of Akt in cells depleted of α2β1 should result in the restoration of their invasive activity. It appeared that treatment with LY294002, which inhibits all Akt isoforms (Akt1, Akt2, Akt3), not only failed to restore the invasive phenotype of melanoma cells but further attenuated their invasive activity. However, treatment of the cells with an Akt1-specific inhibitor significantly increased their invasion. Thus, the stimulating effect of α2β1 integrin on invasion of melanoma cells is realized through a mechanism based on inhibition of one of the Akt isoforms, which in these cells exhibits a noncanonical function consisting in suppression of invasion.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kozlova</LastName>                    <ForeName>N I</ForeName>                    <Initials>NI</Initials>                    <AffiliationInfo>                        <Affiliation>Orekhovich Institute of Biomedical Chemistry, Russian Academy of Sciences, Moscow, 119121, Russia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morozevich</LastName>                    <ForeName>G E</ForeName>                    <Initials>GE</Initials>                    <AffiliationInfo>                        <Affiliation>Orekhovich Institute of Biomedical Chemistry, Russian Academy of Sciences, Moscow, 119121, Russia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ushakova</LastName>                    <ForeName>N A</ForeName>                    <Initials>NA</Initials>                    <AffiliationInfo>                        <Affiliation>Orekhovich Institute of Biomedical Chemistry, Russian Academy of Sciences, Moscow, 119121, Russia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Berman</LastName>                    <ForeName>A E</ForeName>                    <Initials>AE</Initials>                    <AffiliationInfo>                        <Affiliation>Orekhovich Institute of Biomedical Chemistry, Russian Academy of Sciences, Moscow, 119121, Russia. 1938berman@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Biochemistry (Mosc)</MedlineTA>            <NlmUniqueID>0376536</NlmUniqueID>            <ISSNLinking>0006-2979</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D038982">Integrin alpha2beta1</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>31M2U1DVID</RegistryNumber>                <NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.1</RegistryNumber>                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.24</RegistryNumber>                <NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 3.4.24.24</RegistryNumber>                <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="Y">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D038982" MajorTopicYN="N">Integrin alpha2beta1</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30195330</ArticleId>            <ArticleId IdType="pii">BCM83060939</ArticleId>            <ArticleId IdType="doi">10.1134/S0006297918060111</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>